Part B

Billing Codes Decision Could Aid Track-and-Trace Efforts

A Trump administration decision about how biosimilar drugs will be billed could have an important benefit – making it easier to identify which drugs cause

Read More

Part B Demonstration Lacks Patient Monitoring Strategy, Says New Study

by Amanda Conschafter, blog editor The Medicare Part B payment demonstration planned by the Centers for Medicare and Medicaid Services lacks a vital component: a

Read More

New Study: Medicare Fix Could Require Seniors to Pay More for Biosimilars

by Amanda Conschafter, blog editor Government efforts to close Medicare Part D’s so-called donut hole could have unexpected consequences, explains a new study from Avalere

Read More
Back to Top